Related Experiment Video
Updated: Aug 14, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung
Jingyao Zhang1, Linjun Zha2, Ruqiang Liang2,3
1Department of Internal Medicine, Danbury Hospital, Zucker School of Medicine at Hofstra/Northwell, Danbury, CT 06810, USA.
Abstract:
Epidermal growth factor receptor (EGFR)-targeted therapy represents one of the earliest and most established examples of precision oncology in non-small-cell lung cancer (NSCLC), with more than 10 approved agents, including tyrosine kinase inhibitors, bispecific antibodies and antibody-drug conjugates. Over the past two decades, the diagnostic and therapeutic landscape of EGFR-mutant NSCLC has evolved from empiric treatment to mutation subtype-guided strategies, from advanced disease to earlier-stage interventions, and from monotherapy to rational combination regimens. Somatic EGFR mutations remain key predictive biomarkers guiding treatment selection, therapeutic intensification, resistance mechanism-directed treatment, and disease monitoring through plasma circulating tumor DNA burden. In parallel, germline EGFR alterations are increasingly recognized as contributors to inherited lung cancer susceptibility, particularly among never-smokers and familial clusters. Germline EGFR T790M is the best-characterized pathogenic variant, creating a permissive background for multifocal lung nodules and lung adenocarcinoma development, often following acquisition of a second somatic EGFR driver mutation. Recent familial, regional, and paired tumor-normal sequencing studies have expanded the evidence beyond isolated case reports and support an emerging hereditary lung cancer predisposition phenotype. Clinically, germline EGFR should be suspected when EGFR T790M is detected prior to TKI exposure, particularly at variant allele fractions near 50%, or in patients with multifocal ground-glass nodules, multiple primary lung adenocarcinomas, early-onset disease, never/light smoking history, or family history of lung cancer. Confirmation requires germline testing and genetic counseling. This review highlights the current knowledge, recent advances, and future directions in somatic and germline EGFR-mutant NSCLC, emphasizing translational relevance for clinicians and researchers.
Insights
Epidermal growth factor receptor (EGFR) targeted therapy has advanced non-small-cell lung cancer (NSCLC) treatment. Germline EGFR alterations are now recognized as contributing to inherited lung cancer susceptibility, especially in never-smokers.
Area of Science:
- Oncology
- Genetics
- Precision Medicine
Background:
- Epidermal growth factor receptor (EGFR) targeted therapy is a cornerstone of precision oncology for non-small-cell lung cancer (NSCLC).
- The treatment landscape for EGFR-mutant NSCLC has evolved significantly over two decades, shifting towards mutation-guided strategies, earlier interventions, and combination therapies.
- Somatic EGFR mutations are crucial biomarkers for treatment selection, resistance monitoring, and disease surveillance via circulating tumor DNA.
Purpose of the Study:
- To review the current knowledge, recent advances, and future directions in both somatic and germline EGFR-mutant NSCLC.
- To highlight the translational relevance of EGFR alterations for clinicians and researchers.
- To discuss the emerging role of germline EGFR alterations in inherited lung cancer predisposition.
Main Methods:
- Review of current literature and recent studies on somatic and germline EGFR mutations in NSCLC.
- Analysis of diagnostic and therapeutic evolution in EGFR-mutant NSCLC.
- Discussion of clinical implications and genetic counseling for germline EGFR alterations.
Main Results:
- Somatic EGFR mutations remain critical for guiding NSCLC treatment and monitoring response.
- Germline EGFR alterations, particularly T790M, are increasingly implicated in inherited lung cancer susceptibility, especially in familial clusters and never-smokers.
- Clinical suspicion for germline EGFR alterations is warranted in specific patient profiles, necessitating germline testing and genetic counseling.
Conclusions:
- EGFR-targeted therapies have transformed NSCLC treatment, with somatic mutations serving as key biomarkers.
- Germline EGFR alterations represent an emerging area of hereditary lung cancer predisposition, requiring clinical awareness and genetic evaluation.
- Continued research into both somatic and germline EGFR alterations is crucial for advancing personalized lung cancer care.
